[{"address1": "11 Great Valley Parkway", "city": "Malvern", "state": "PA", "zip": "19355", "country": "United States", "phone": "484 328 4701", "website": "https://www.ocugen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.", "fullTimeEmployees": 65, "companyOfficers": [{"maxAge": 1, "name": "Dr. Shankar  Musunuri M.B.A., Ph.D.", "age": 59, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 864246, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uday B. Kompella Ph.D.", "age": 56, "title": "Co-founder & Independent Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 60000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Arun  Upadhyay Ph.D.", "age": 40, "title": "Chief Scientific Officer and Head of Research & Development", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 598056, "exercisedValue": 0, "unexercisedValue": 4000}, {"maxAge": 1, "name": "Mr. Ramesh  Ramachandran C.M.A., CPA, M.B.A.", "title": "Principal Financial Officer & Principal Accounting Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "John  Kouch J.D.", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tiffany J. Hamilton M.B.A.", "title": "AVP & Head of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen  Craft", "title": "Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Shine M.B.A.", "title": "Senior Vice President of Commercial", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jyothy  Pillai M.S.", "title": "VP & Head of Regulatory & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Huma  Qamar CMI, M.D., M.P.H.", "age": 39, "title": "Chief Medical Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 9, "overallRisk": 10, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.8524, "open": 0.86, "dayLow": 0.8235, "dayHigh": 0.8798, "regularMarketPreviousClose": 0.8524, "regularMarketOpen": 0.86, "regularMarketDayLow": 0.8235, "regularMarketDayHigh": 0.8798, "beta": 3.766, "forwardPE": -3.21521, "volume": 5096568, "regularMarketVolume": 5096568, "averageVolume": 3747873, "averageVolume10days": 3907830, "averageDailyVolume10Day": 3907830, "bid": 0.8363, "ask": 0.8879, "bidSize": 900, "askSize": 2900, "marketCap": 249777776, "fiftyTwoWeekLow": 0.37, "fiftyTwoWeekHigh": 2.105, "priceToSalesTrailing12Months": 53.144207, "fiftyDayAverage": 0.94042, "twoHundredDayAverage": 1.298945, "currency": "USD", "enterpriseValue": 214896256, "floatShares": 283905482, "sharesOutstanding": 291320000, "sharesShort": 56995210, "sharesShortPriorMonth": 50645227, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.19559999, "heldPercentInsiders": 0.01407, "heldPercentInstitutions": 0.27528, "shortRatio": 14.01, "shortPercentOfFloat": 0.199, "impliedSharesOutstanding": 295600992, "bookValue": 0.158, "priceToBook": 5.426582, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -51144000, "trailingEps": -0.19, "forwardEps": -0.26, "lastSplitFactor": "1:60", "lastSplitDate": 1569801600, "enterpriseToRevenue": 45.723, "enterpriseToEbitda": -4.253, "52WeekChange": 1.3037634, "SandP52WeekChange": 0.2764505, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "OCGN", "underlyingSymbol": "OCGN", "shortName": "Ocugen, Inc.", "longName": "Ocugen, Inc.", "firstTradeDateEpochUtc": 1417617000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "169c2c50-f570-39a4-b709-68c305b79bbd", "messageBoardId": "finmb_303874231", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.8574, "targetHighPrice": 8.0, "targetLowPrice": 4.0, "targetMeanPrice": 6.25, "targetMedianPrice": 6.5, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 38696000, "totalCashPerShare": 0.134, "ebitda": -50529000, "totalDebt": 6783000, "quickRatio": 2.455, "currentRatio": 2.58, "totalRevenue": 4700000, "debtToEquity": 16.695, "revenuePerShare": 0.018, "returnOnAssets": -0.47981, "returnOnEquity": -1.0329499, "operatingMargins": -11.665489, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]